Pyrazolopyridine and pyrrolopyridine multikinase inhibitors

A compound represented by Formula (1) of:

• a pharmaceutically acceptable salt thereof,
• wherein
• Ar is an arylene linking group selected from the following formulae:
• wherein * represents a binding site to the nitrogen atom, and ** represents a binding site to T;
• T is —(O)n—R;
• R is selected from the group consisting of a C1-C6 alkyl group, a C3-C8 cycloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a phenyl group, a tetrahydrofuranyl group, a tetrahydrothiopyranyl group, a 1-oxotetrahydrothiopyranyl group, a 1,1-dioxotetrahydrothiopyranyl group, and a tetrahydropyranyl group, wherein each of these groups may be optionally substituted by one to three substituents independently selected from the group consisting of a hydroxyl group, an oxo group, a halogen atom, and a C1-C6 alkoxy group;
• n is 0 or 1;
• X is O, S(O)m, CH2, C═O, or NR1, wherein m is an integer of 0 to 2, and R1 is H or a C1-C3 alkyl group;
• R2, R3 and R4 are independently selected from the group consisting of a hydrogen atom and C1-C3 alkyl, where the alkyl group may be optionally substituted by one to three substituents independently selected from the group consisting of a hydroxyl group, an oxo group, a C1-C3 alkoxy group, and a C1-C3 alkoxy-C1-C3 alkoxy group;
• or
• R2 and R3 together with the urea structure containing the nitrogen atoms to which they are bonded may form a 5- or 6-membered heterocycle, which may be optionally substituted by one to three substituents independently selected from the group consisting of an oxo group and a hydroxyl group;
• and
• Y is CH or N.